Previous close | 20.56 |
Open | 20.26 |
Bid | 20.51 x 200 |
Ask | 20.58 x 400 |
Day's range | 19.65 - 20.67 |
52-week range | 19.65 - 79.65 |
Volume | |
Avg. volume | 658,361 |
Market cap | 1.104B |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.76 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 66.77 |
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.